Advanced searches left 3/3

Preterm Birth - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 21 July 2022

* If you want to update the article please login/register

Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls

Comparing to a historical control group, primary results: To determine whether a cohort of women who are screened for the PreTRMu00ae test and later managed according to a pre-specified protocol will have statistically significant decreases in either composite neonatal morbidity and mortality, or length of neonatal hospital stay. Results of Ultrasound Obstet Gynecol 2011; 38:18-19:36:18-31 Results Secondary findings: To see if women who were screened for the PreTRMu00ae test and then treated with a pre-specified treatment protocol will have a statistically significant decrease in the number of premature and confirmed preterm births, the total length of hospital stay for any preterm birth, and the total length of hospital stay for any preterm birth.

Source link: https://clinicaltrials.gov/ct2/show/NCT03151330


Select Nutrient and Gene Variant Analysis in a Targeted Diet and Lifestyle Intervention Reduces Preterm Birth (SNGLI-PTB)

Hypothesis: 2022 Diet and lifestyle changes, as well as diet and lifestyle changes, may greatly reduce the likelihood of preterm birth. Secondary Hypothesis: U2022 Diet and lifestyle education, as well as gene sequencing and refinement of restricted genomics and nutrient biomarkers will significantly reduce the risk of preeclampsia, gestational diabetes mellitus, young for gestational age neonates, and neonatal hospitalizations within the first two weeks of life. Hypotheses Based on Hypotheses Experimentation Hypotheses: A gene variant pattern that predicts PTB will emerge. Objectives: PTB rates for both intervention and non-intervention groups have been established. Determine whether diet and lifestyle changes, as well as restricted genomics and micronutrient biomarkers applied to a 100% Medicaid population are linked to reduced PTB, pre-E, GDM, SGA, LGA, and neonatal hospitalizations. Determine whether the decline in pregnancy and neonatal morbidities is accompanied by a decrease in related net health care costs.

Source link: https://clinicaltrials.gov/ct2/show/NCT05436119


Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Late term infants also have a higher mortality for all causes when compared to term infants. Antinatal corticosteroids have been shown to be helpful in women at risk of preterm delivery prior to 34 weeks, but no such studies have been performed in those likely to deliver in the late preterm period. This trial will examine whether antenatal corticosteroids can reduce the need for respiratory assistance and, in the absence of short-term outcomes in the late preterm infant, will be considered. This research will conclude that if antenatal corticosteroids can reduce the need for respiratory assistance and, ultimately, minimize the risk of special care nursery admissions and improved short-term outcomes. With an anticipated late preterm delivery, the first follow-up study will determine if the beneficial effects of betamethasone on lung function in children at 6 years of age of mothers randomized to betamethasone will continue in children at 6 years of age. Neonatal respiratory morbidity is attributed to an elevated risk of adverse childhood respiratory disease. Late prenatal betamethasone therapy is shown to improve cognitive function, and whether there are any long-term effects of what is perceived as transient neonatal hypoglycemia. The differential Ability Scales 2nd Edition core components of the general conceptual capability include verbal skills, non-verbal reasoning, and spatial literacy.

Source link: https://clinicaltrials.gov/ct2/show/NCT01222247


Characterization of Pre-Term Neonatal Skin by Diffuse Reflectance Spectroscopy Pilot Study

This is a cross-sectional, pilot study to determine the response of neonatal premature skin to DRS when excited with a white light source, as well as a baseline of how the collected spectra change with the epidermal layer maturation after birth. On the study population admitted to the Neonatal Intensive Care Unit, DRS spectra and BiliChek measurements will be conducted. The pilot results will be used to determine whether Diffuse Reflectance Spectra can be used to extract optical measurements on skin ages, as well as hemoglobin, melanin, and bilirubin concentrations. Diffuse Reflectance Spectra for Each Chromophore will be compared to published absorbance spectra for each chromophore. The extracted bilirubin contribution measured by the Diffuse Reflectance Spectroscopy Spectra using linear regression and Pearson's correlation coefficient will be compared to the extracted bilirubin contribution measured from the Diffuse Reflectance Spectroscopy spectra using linear regression and estimated using Pearson's correlation coefficient.

Source link: https://clinicaltrials.gov/ct2/show/NCT05127044


Pentoxifylline Dose Optimization in Preterm Neonatal Late Onset Sepsis

Despite effective antibiotic therapy and immaturity of the immune system in preterm neonates, this severe sepsis-related mortality and morbidity is linked to poor antibiotic therapy. There are strong signals that premature neonates with sepsis may benefit from pentoxifylline therapy. Objective: The main aim is to determine in what optimal dose pentoxifylline should be used in premature infants suffering from sepsis. Study design: Dose optimization research in preterm born infants with delayed onset sepsis and elevated inflammation in preterm born infants with delayed onset sepsis and elevated inflammation. In all previous studies, the starting dose would be the same as predicted. Preterm born neonates with a gestational age of less than 30 weeks, as well as reports of late onset sepsis and relevant inflammation are eligible for admission. When 3 patients are treated with a specific dosage, a decision will be made whether to increase or decrease the dosage for the next three patients. Secondary endpoints include researching the inflammatory and immunological changes of infants during sepsis with pentoxifylline therapy by testing metabolomic biomarkers of the signalling and perceptive lipid platform, as well as 91 inflammatory proteomics. Although evidence regarding participation, health, and group relatedness is lacking, there are already reports on the dose/reponse curve for patients with sepsis in our neonatal intensive care unit, but no reports on the dose/response curve exist. Pentoxifylline, according to a meta-analysis, prolongs the life of premature infants suffering from sepsis, while preterm infants suffering from sepsis, and pentoxifylline is well tolerated. A small amount of additional blood will be collected either from arterial lines or during regular blood drawing during the course of the investigation.

Source link: https://clinicaltrials.gov/ct2/show/NCT04152980


Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

Both preterm birth and infant survival rates are on the rise globally, so premature birth is an emerging and significant risk factor for hypertension and cardiovascular disease. An improved understanding of why hypertension and cardiovascular disease in young adulthood in people born preterm can help reduce cardiovascular disease's burden. In subjects born preterm, investigators will then determine if blocking UA formation raises SSBP and cardiovascular function.

Source link: https://clinicaltrials.gov/ct2/show/NCT04026776


Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Following initial research-specific surgery, Adverse events following initial study-specific surgery will be included in the treatment period, as well as Days 1-28 or the last day of study drug withdrawal if early withdrawal of study material. The following data will be collected and recorded while the participant is on study drug use Days 7, 14, 21, and 28 of study drug administration Date, time, amount, and route of study drug use The following data will be collected and reported during the participant's participation in study drug use: The following data will be collected and documented: Actual weight on study days 7, 14, 21, and 28 of study drug administration Date, time, date, duration, and route of study drug do If the administration route is enteral: During and following the first dose of study drug or dose escalation: MAP at the start of enteral therapy, every 15 minutes for 90 minutes, then every 30 minutes for 60 minutes, then hourly for four hours, and finally in the remaining 2 hours before the next dose. MAP reveals the following information will be collected and stored while the participant is weaning from a study drug: date, time, measurement, and route of study drug administration. If performed on local requirements of care, a revalidation study may occur on the last day of wean Echocardiogram and cardiac catheterization results, if done properly; if performed according to a local standard of care. Follow-up Period The last study drug dose should occur on day 28 for those participants who complete the treatment period; or after the last weaning dose for those participants who require weaning is included in the follow-up period.

Source link: https://clinicaltrials.gov/ct2/show/NCT04447989

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions